Education
About Us
Working with TipRanks
Follow Us
Protara Therapeutics, Inc. (TARA)
:TARA
TARA Analyst Ratings
Strong Buy
5 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
TARA Stock 12 Month Forecast
Average Price Target
$24.20
▲(469.41% Upside)
| Highest Price Target$30.00 | Average Price Target$24.20 | Lowest Price Target$21.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
H.C. Wainwright
$23
Buy
441.18%
Upside
Reiterated
09/17/25
JonesTrading
$21
Buy
394.12%
Upside
Reiterated
09/12/25
LifeSci Capital
$22
Buy
417.65%
Upside
Reiterated
08/21/25
Protara Therapeutics' IV Choline Chloride: Promising Solution for Liver Dysfunction and Intestinal FailureWe recently interviewed three US-based KOLs with specialized training in, and experience prescribing, parenteral nutrion (PN) to 1) learn more about the state-of-the-art in PN care, 2) discuss unmet needs in the space (including around liver dysfuncon) 3) discuss clinical posioning and driv ers of adopon f or IV choline chloride, and 4) gauge reacons t o the THRIVE-3 trial design.
Scotiabank
$12
Buy
182.35%
Upside
Reiterated
05/09/25
Cantor Fitzgerald
―
Buy
―
Initiated
03/14/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
H.C. Wainwright
$23
Buy
441.18%
Upside
Reiterated
09/17/25
JonesTrading
$21
Buy
394.12%
Upside
Reiterated
09/12/25
LifeSci Capital
$22
Buy
417.65%
Upside
Reiterated
08/21/25
Protara Therapeutics' IV Choline Chloride: Promising Solution for Liver Dysfunction and Intestinal FailureWe recently interviewed three US-based KOLs with specialized training in, and experience prescribing, parenteral nutrion (PN) to 1) learn more about the state-of-the-art in PN care, 2) discuss unmet needs in the space (including around liver dysfuncon) 3) discuss clinical posioning and driv ers of adopon f or IV choline chloride, and 4) gauge reacons t o the THRIVE-3 trial design.
Scotiabank
$12
Buy
182.35%
Upside
Reiterated
05/09/25
Cantor Fitzgerald
―
Buy
―
Initiated
03/14/25
Best Analysts Covering Protara Therapeutics
1 Month
xxx
Success Rate
5/15 ratings generated profit
Average Return
+2.45%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 33.33% of your transactions generating a profit, with an average return of +2.45% per trade.
3 Months
xxx
Success Rate
6/15 ratings generated profit
Average Return
+27.86%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 40.00% of your transactions generating a profit, with an average return of +27.86% per trade.
1 Year
2 Years
xxx
Success Rate
8/15 ratings generated profit
Average Return
+11.05%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 53.33% of your transactions generating a profit, with an average return of +11.05% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
TARA Analyst Recommendation Trends
Rating
Apr 25
May 25
Jun 25
Aug 25
Sep 25
Strong Buy
7
11
8
11
9
Buy
1
1
0
0
0
Hold
4
3
2
0
0
Sell
5
5
3
0
0
Strong Sell
0
0
0
0
0
total
17
20
13
11
9
Each month's total comprises the sum of three months' worth of ratings.
TARA Financial Forecast
TARA Stock Forecast FAQ
What is TARA’s average 12-month price target, according to analysts?
Based on analyst ratings, Protara Therapeutics, Inc.’s 12-month average price target is 24.20.
What is TARA’s upside potential, based on the analysts’ average price target?
Protara Therapeutics, Inc. has 469.41% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is TARA a Buy, Sell or Hold?
Protara Therapeutics, Inc. has a consensus rating of Strong Buy which is based on 5 buy ratings, 0 hold ratings and 0 sell ratings.
What is Protara Therapeutics, Inc.’s price target?
The average price target for Protara Therapeutics, Inc. is 24.20. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $30.00 ,the lowest forecast is $21.00. The average price target represents 469.41% Increase from the current price of $4.25.
The highest analyst price target is $30.00 ,the lowest forecast is $21.00. The average price target represents 469.41% Increase from the current price of $4.25.
What do analysts say about Protara Therapeutics, Inc.?
Protara Therapeutics, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.
How can I buy shares of TARA?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.